Loading stockRelated stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockRelated stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Traws Pharma (TRAW) generated about n/a in revenue and -$19 million in net income (a 328.7% net margin) over the trailing twelve months, growing at roughly 64.6% a year. Figures are from SEC filings; this is analysis, not investment advice.
Traws Pharma reported about -$19 million in net loss over the trailing twelve months, a net margin of roughly 328.7%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Traws Pharma runs an operating margin of about -640.7%, a net margin of about 328.7%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
Traws Pharma's revenue has compounded at roughly 64.6% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside TRAW's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 15 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 26 Jun 2026. How this is calculated.
Fiscal year ends Dec.